Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
DVkQFxCN9GkE6eFs
Listen
